AIAI — NetraMark Holdings Share News
0.000.00%
Last trade - 00:00- CA$49.21m
- CA$46.03m
- CA$0.43m
Brief: Netramark Signs Four New Contracts With A Leading Global Pharmaceutical Company To Enhance Clinical Trial Insights
Brief: Asklepion Pharmaceuticals Signs Contract To Utilize Netramark Technology In Phase III Pediatric Cardiac Study
Brief: NetraMark Holdings Signs Contract With AlgoTx To Enhance Clinical Trial Design For ATX01
Brief: Netramark And Worldwide Clinical Trials Announce Agreement To Transform Clinical Trial Design With Ai-Powered Precision
Brief: Netramark And Worldwide Clinical Trials Announce Agreement To Transform Clinical Trial Design With Ai-Powered Precision
Brief: Netramark Announces Collaboration Agreement With Nimh To Analyze Clinical Trial Data On The Use Of Ketamine In Psychiatric Disorders
Brief: NetraMark Provides Business Update And Highlights Progress
Brief: NetraMark's AI-Based Technology Identifies Significant Drivers Of Efficacy And Placebo
Brief: Healthcare Strategy Leader Joins Netramark Advisory Board
Brief: Nurosene Health Announces Closing Of Private Placement
Brief: Nurosene Health Announces Research Partnership
Brief: Nurosene Announces George Achilleos As President & Chief Operating Officer
Brief: Global Pop Icon Nick Jonas Invests In AI-Driven Mental Health Company Nurosene
Brief: Former Apple Global Head Of Ecommerce Solutions Marcus Delano East Joins Nurosene Advisory Board